Cerebrolysin.
Cerebrolysin is a peptide preparation produced by the enzymatic breakdown of purified porcine (pig) brain proteins, yielding a mixture of low-molecular-weight peptides and free amino acids.
Cerebrolysin is a peptide preparation produced by the enzymatic breakdown of purified porcine (pig) brain proteins, yielding a mixture of low-molecular-weight peptides and free amino acids. Cerebrolysin is research / preclinical, and PepCue grades its published evidence C tier (59/100). Also known as porcine brain peptide preparation. This is a research reference, not medical or dosing advice.
What it is
Cerebrolysin is a peptide preparation produced by the enzymatic breakdown of purified porcine (pig) brain proteins, yielding a mixture of low-molecular-weight peptides and free amino acids. It is manufactured by EVER Neuro Pharma and given by injection or intravenous infusion rather than orally. Marketed as a neurotrophic and neuroprotective agent, it has been studied across acute ischaemic stroke, vascular dementia, Alzheimer's disease and traumatic brain injury. It is one of the most extensively trialed brain-peptide preparations, yet its clinical benefit remains genuinely contested.
How it works
Because Cerebrolysin is a complex biological mixture rather than a single molecule, its mechanism is described as pleiotropic. The peptide fraction is proposed to mimic endogenous neurotrophic factors, supporting neuronal survival, synaptic plasticity and neurogenesis. Preclinical work also suggests reduced excitotoxicity, anti-apoptotic signaling and effects on amyloid processing. The precise active components and their targets in humans are not fully defined.
Mechanism pathways
Raising growth factors that support neuronal survival, synapse formation, and plasticity.
Neurotrophic factors are proteins that keep neurons alive, guide the formation and strengthening of synapses, and support the structural changes underlying learning. The best-studied is brain-derived neurotrophic factor, which acts on the TrkB receptor tyrosine kinase to activate PI3K and Akt signalling for survival and MAPK signalling for growth, and which is required for long-term potentiation, the cellular process most closely associated with memory formation. Nerve growth factor acts similarly through TrkA. A separate system involves hepatocyte growth factor and its receptor tyrosine kinase c-Met, which in neurons is associated with dendritic spine formation and synaptogenesis. Compounds in this group approach the same idea from different angles. Several are short peptides derived from fragments of adrenocorticotropic hormone that lack the hormone's melanocortin-driven corticotropic activity, so they do not raise cortisol. Their best-characterised action in animal and cell studies is upregulation of BDNF and its TrkB receptor in the hippocampus and cortex, along with increased nerve growth factor expression, plus modulation of monoaminergic signalling and inhibition of enkephalin-degrading enzymes. One member of this subgroup is a chemically modified variant designed for greater stability, whose mechanism is inferred from the parent rather than independently established. Others are complex biological mixtures rather than single molecules, prepared from brain tissue, and their activity is attributed to many peptide interactions acting together. Proposed actions include mimicking endogenous neurotrophic factors, supporting neuronal energy metabolism, reducing excitotoxicity, and providing anti-apoptotic and antioxidant effects. Because the active components are not fully defined, batch consistency is an intrinsic issue with this format. A further compound is reported to raise BDNF transcription while inhibiting a cytokine signalling pathway, with downstream reduction of an enzyme implicated in abnormal tau phosphorylation. Another was developed to potentiate hepatocyte growth factor signalling at c-Met. Several honest caveats apply. Most of this evidence comes from rodent and cell-culture work. Some of the brain-derived mixtures are approved and widely used in certain countries while remaining unapproved and unavailable in others, and independent assessments of their clinical benefit have been mixed. For the c-Met compound, the central biochemical evidence for its proposed mechanism came from a publication that was retracted for data fabrication, and c-Met is a well-established oncology target, so chronic potentiation raises an unresolved risk question that no human study has addressed.
The evidence
Cerebrolysin has been evaluated in numerous randomized controlled trials, and two Cochrane systematic reviews summarize the best available evidence. The 2023 Cochrane review of acute ischaemic stroke concluded that Cerebrolysin probably has little or no beneficial effect on death or clinical outcome, and it flagged a possible increase in non-fatal serious adverse events, rating certainty of evidence as low to moderate. The 2019 Cochrane review of vascular dementia found possible short-term benefits on cognition and global function but did not recommend routine use, citing small trials, short follow-up and high risk of bias. Several included trials were industry-sponsored, which further tempers confidence. Taken together, the clinical picture is mixed and unsettled rather than clearly positive. The underlying trial set has a distinctive geography: a large share of the randomized evidence originates from centers in Eastern Europe, the CIS, China and parts of Asia, often with the manufacturer as sponsor or provider of study drug, and a substantial portion of the earlier literature was published in languages other than English, which complicates independent appraisal. Trial durations are typically short, on the order of weeks of treatment with follow-up rarely extending to a year, and outcome scales differ between studies, which limits pooling. Later work has continued in narrower settings: a randomized pilot study of speech therapy combined with Cerebrolysin for nonfluent aphasia after acute ischaemic stroke was published in Stroke in 2025, and clinical reviews of neuroprotective and neuroregenerative agents after severe traumatic brain injury continue to describe the evidence as inconclusive. What remains unknown is central rather than peripheral: the active components of the mixture are not identified, so batch-to-batch consistency cannot be verified by potency assay against a defined molecule, and no biomarker predicts response. Even so, Cerebrolysin is the best-studied compound in the animal-tissue peptide category by a wide margin, since preparations such as cortexin, thymalin and vilon have no comparable body of randomized evidence and have never been assessed by Cochrane.
The evidence, in brief
A porcine brain-derived peptide and amino-acid mixture given parenterally, and one of the most heavily trialed compounds in this category. Two Cochrane reviews temper the enthusiasm: the 2023 stroke review concluded it probably has little or no effect on death or clinical outcome and flagged a possible increase in non-fatal serious adverse events, while the 2019 vascular-dementia review found only possible short-term cognitive benefit amid small, biased, often industry-sponsored trials. Not FDA-approved, though registered in various other countries.
- Ziganshina LE et al.: Cerebrolysin for acute ischaemic strokeCochrane Database Syst Rev, 2023 (PMID 37818733)
- Cui S et al.: Cerebrolysin for vascular dementiaCochrane Database Syst Rev, 2019 (PMID 31710397)
Evidence maturity
An evidence-only reading: approval status, human vs preclinical data, mechanism and safety. Popularity never raises it. Research file #011
Some human signal atop preclinical work; gaps remain.
Studied in human clinical trials; evidence is meaningful.
Claim receipts
Popular claims about Cerebrolysin, checked against the state of the evidence. The verdict describes evidence maturity, never an invented study result.
This has been tested rather than left untested: the 2023 Cochrane review of acute ischaemic stroke concluded it probably has little or no beneficial effect on death or clinical outcome.
The 2019 Cochrane review of vascular dementia found possible short-term benefit on cognition and global function, but did not recommend routine use, citing small trials, short follow-up and high risk of bias.
Among animal-tissue peptide preparations it is the only one with enough randomized trials to have been assessed twice by Cochrane; cortexin, thymalin and vilon have nothing comparable.
A large share of the randomized evidence comes from a narrow set of regions, often with the manufacturer as sponsor or provider of study drug, and much of the older literature was published in languages other than English, which complicates independent appraisal.
Clinical reviews of neuroprotective and neuroregenerative agents after severe traumatic brain injury continue to describe the evidence as inconclusive.
The 2023 Cochrane stroke review flagged a possible increase in non-fatal serious adverse events, and the active components of the mixture are not identified, so batch consistency cannot be verified by potency assay.
Safety profile
In trials Cerebrolysin was generally reported as well tolerated, with reactions such as dizziness, headache, agitation, sweating and injection-site effects. Cochrane reviewers noted a possible signal of increased non-fatal serious adverse events in the stroke setting, though this finding was uncertain, and that uncertainty is itself a finding: the trials were not individually powered for safety, adverse-event definitions varied between studies, and reporting completeness differed, so the signal can be neither confirmed nor dismissed from the existing data. As a porcine-derived biological given parenterally, allergic and hypersensitivity reactions are a theoretical concern, and product information in the countries where it is registered describes contraindications including known hypersensitivity, status epilepticus and severe renal impairment. Rapid infusion has been associated with transient reactions such as flushing, dizziness and palpitations. Because the preparation is a complex mixture rather than a single characterized molecule, immunogenicity and lot-to-lot variability are harder to evaluate than for a defined peptide drug. Material obtained outside licensed pharmacy channels adds contamination and counterfeit risk on top of the pharmacological questions, since parenteral products require verified sterility and endotoxin limits. Adequate monitoring in a trial setting includes supervised administration, observation for infusion reactions, renal function assessment, seizure history review and systematic adverse-event capture. It is a clinical product, not a dietary supplement, and any use is a medical decision.
Compound notes
- Cerebrolysin is a peptide preparation made by enzymatic breakdown of purified porcine brain proteins, yielding a mixture of low-molecular-weight peptides and free amino acids.
- Manufactured by EVER Neuro Pharma, it is given by injection or intravenous infusion rather than orally.
- Because it is a complex biological mixture rather than a single molecule, its mechanism is described as pleiotropic: the peptide fraction is proposed to mimic endogenous neurotrophic factors supporting neuronal survival and synaptic plasticity.
- It is among the most extensively trialed brain-peptide preparations, studied in acute ischaemic stroke, vascular dementia, Alzheimer's disease and traumatic brain injury, yet its clinical benefit remains genuinely contested.
Both are animal-brain-derived peptide mixtures used outside the US. Cerebrolysin is porcine and has been through numerous randomized trials and two Cochrane reviews; cortexin is bovine and has far less international trial scrutiny.
- Not FDA-approved and not marketed in the United States, though registered and used clinically in a number of countries across Europe, Asia, the CIS and Latin America.
- The 2023 Cochrane review in acute ischaemic stroke concluded it probably has little or no beneficial effect on death or clinical outcome, and flagged a possible increase in non-fatal serious adverse events.
- Reported reactions include dizziness, headache, agitation, sweating and injection-site effects; as a porcine-derived parenteral biological, hypersensitivity is a theoretical concern.
Regulatory status
Cerebrolysin is not approved by the US FDA and is not marketed in the United States. It is registered and used clinically in a number of countries across Europe, Asia, the CIS and Latin America. This entry is educational only and contains no dosing guidance.
Sold research-use-only; human evidence is limited or preclinical.
By the numbers
- 01Mixture of peptides and free amino acids derived from purified porcine brain tissue.
- 02Administered by injection or intravenous infusion, not orally.
- 03Studied in stroke, vascular dementia, Alzheimer's disease and traumatic brain injury.
- 04Two Cochrane reviews (stroke 2023; vascular dementia 2019) reach cautious, non-endorsing conclusions.
- 05Evidence quality is limited by small trials, risk of bias and industry sponsorship.
- 06Not FDA-approved, but approved and marketed in various other countries.
Cerebrolysin: research formats
Choose the format you are researching to see route-specific notes.
Given by injection or intravenous infusion, never orally. Not FDA-approved or marketed in the US.
Cerebrolysin is a mixture of low-molecular-weight peptides and free amino acids produced by enzymatic breakdown of purified porcine brain proteins. The format point that matters is that it is a parenteral product: it is administered by injection or intravenous infusion, not taken orally. It is registered and used clinically in a number of countries in Europe, Asia, the CIS, and Latin America, but it is not FDA-approved and not marketed in the United States.
Where Cerebrolysin is registered it is a prescription medicine with its own approved product information, which this page does not reproduce. There is no US label to cite.
The clinical benefit is genuinely contested. Two Cochrane reviews, on stroke in 2023 and vascular dementia in 2019, reached cautious, non-endorsing conclusions, and the trial base is limited by small studies, risk of bias, and industry sponsorship.
Sources
Every factual claim above resolves to a real, published source.
- Cerebrolysin for acute ischaemic strokeZiganshina LE et al. Cochrane Database Syst Rev, 2023 (PMID 37818733)
- Cerebrolysin for vascular dementiaCui S et al. Cochrane Database Syst Rev, 2019 (PMID 31710397)
- Speech Therapy Combined With Cerebrolysin in Enhancing Nonfluent Aphasia Recovery After Acute Ischemic Stroke: ESCAS Randomized Pilot StudyHomberg V, Jianu DC, et al. Stroke. 2025 (PMID 39957612)
- Neuroprotective and neuroregenerative drugs after severe traumatic brain injury: A narrative review from a clinical perspectiveGrgac I, Herzer G, et al. Wien Klin Wochenschr. 2024 (PMID 38748062)
- Cochrane Library search: CerebrolysinLive search of Cochrane systematic reviews and trial records
Cite this page
PepCue. “Cerebrolysin: the evidence.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/p/cerebrolysin.
Log your doses, run the vial math, and keep a provider-ready record in PepCue.